NasdaqGS - Delayed Quote • USD
Mesoblast Limited (MESO)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:49 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -0.32 | -0.4 | -0.72 | -0.78 |
| Low Estimate | -0.32 | -0.4 | -0.76 | -0.79 |
| High Estimate | -0.32 | -0.4 | -0.68 | -0.78 |
| Year Ago EPS | -0.24 | -0.3 | -1.11 | -0.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | 7.3M | 7.75M |
| Low Estimate | 1.8M | 2M | 6.9M | 7.5M |
| High Estimate | 1.8M | 2M | 7.7M | 8M |
| Year Ago Sales | -- | -- | 7.5M | 7.3M |
| Sales Growth (year/est) | -- | -- | -2.70% | 6.20% |
Earnings History
| CURRENCY IN USD | 9/30/2022 | 12/31/2022 | 3/31/2023 | 6/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.28 | -0.33 | -0.31 |
| EPS Actual | -0.24 | -0.3 | -0.26 | -0.28 |
| Difference | 0.09 | -0.02 | 0.07 | 0.03 |
| Surprise % | 27.30% | -7.10% | 21.20% | 9.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.32 | -0.4 | -0.72 | -0.78 |
| 7 Days Ago | -0.32 | -0.4 | -0.72 | -0.78 |
| 30 Days Ago | -0.32 | -0.4 | -0.72 | -0.78 |
| 60 Days Ago | -0.32 | -0.4 | -1.15 | -1.13 |
| 90 Days Ago | -0.32 | -0.4 | -1.15 | -1.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MESO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -33.30% | -- | -- | 1.60% |
| Next Qtr. | -33.30% | -- | -- | 10.50% |
| Current Year | 35.10% | -- | -- | 5.20% |
| Next Year | -8.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 48.80% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Related Tickers
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0200
0.00%
CADL Candel Therapeutics, Inc.
5.17
-5.31%
ADIL Adial Pharmaceuticals, Inc.
1.9300
-11.06%
CRDF Cardiff Oncology, Inc.
4.3500
-0.46%
RLYB Rallybio Corporation
1.7600
+5.39%
AVTX Avalo Therapeutics, Inc.
11.63
-3.16%
NKGN NKGen Biotech, Inc.
1.1060
+28.60%
IBIO iBio, Inc.
1.7200
-2.82%
ELYM Eliem Therapeutics, Inc.
3.8500
-7.89%
VNDA Vanda Pharmaceuticals Inc.
5.11
+2.82%